Nasdaq · Healthcare
Contineum Therapeutics, Inc. (CTNM)
As-reported financials and recent SEC filings for Contineum Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
—
Net income
$-60.0M
Net margin
—
Diluted EPS
$-2.17
ROE
-23.0%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2024 |
|---|---|---|---|
| Revenue | — | $0 | $50.0M |
| Gross profit | — | — | — |
| Operating income | $-68.1M | $-50.9M | $16.1M |
| Net income | $-60.0M | $-42.3M | $22.7M |
| Diluted EPS | $-2.17 | $-2.18 | $0.01 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →1442026-07-01
View on EDGAR →42026-07-01
View on EDGAR →42026-07-01
View on EDGAR →1442026-06-30
View on EDGAR →1442026-06-30
View on EDGAR →1442026-06-30
View on EDGAR →42026-06-26
View on EDGAR →Largest Healthcare peers
Go deeper on CTNM
Search Contineum Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.